What are you talking about? mLovenox sales were lighter than some of us on this board estimated however they were not lower than NVS/MNTA expected. NVS/MNTA Q4 sales of mLovenox were very solid just not as spectacular as some of us thought as a result of a bigger than expected inventory drawdown.
I feel my statement "...NVS, MNTA's partner in the sale of generic Lovenox, announced lower sales of it than expected this past quarter" was accurate. I said "expected of it", not "than they expected".
I did so because the OP seemed more than anxious to make an earnings play, and I wanted to give him a reason to do more DD. I will admit that I do not consider myself an expert on NVS/MNTA financial matters, which is why I made a broad statement.
Since you referenced another board, why not make your statement there, and I will respond to it there also?